A body of research has indicated that OGG1 Ser326Cys, XRCC1 Arg399Gln, APE1 Asp148Glu, and APE1-141T/G polymorphisms may serve as useful predictors of clinical outcomes in patients with advanced inoperable NSCLC who will receive platinum-based chemotherapy [104]. The gene discussed is APEX1; the disease is non-small cell lung carcinoma.